Familial mediterranean fever as an emerging clinical model of atherogenesis associated with low-grade inflammation

Open Cardiovascular Medicine Journal

Volumn 4, Issue SPEC. ISSUE 1, 2010, Pages 51-56

  Yüksel, Şahru ^a   Ayvazyan, Lilit ^b   Gasparyan, Armen Yuri ^c  

^a BOGAZICI UNIVERSITY   (Turkey)

^b YEREVAN STATE MEDICAL UNIVERSITY   (Armenia)

^c DUDLEY GROUP OF HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Atherosclerosis; Colchicine; Endothelial dysfunction; Familial mediterranean fever; Neutrophils; Platelets

Indexed keywords

C REACTIVE PROTEIN; COLCHICINE; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MUTANT PROTEIN; PROTEIN MEFV; PYRIN PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ABSENCE OF SIDE EFFECTS; AMYLOIDOSIS; ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CELL INTERACTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; FAMILIAL MEDITERRANEAN FEVER; GENE MUTATION; HEART INFARCTION; HUMAN; HYPERCOAGULABILITY; INFLAMMATORY DISEASE; ISCHEMIC HEART DISEASE; LEUKOCYTE ACTIVATION; MODEL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; VASCULAR ENDOTHELIUM;

EID: 78249256660     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401004010051     Document Type: Article

References (87)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-57.
2. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
3. Ikeda U. Inflammation and coronary artery disease. Curr Vasc Pharmacol 2003; 1: 65-70.
4. Ferri C, Croce G, Cofini V, et al. C-reactive protein: interaction with the vascular endothelium and possible role in human atherosclerosis. Curr Pharm Des 2007; 13: 1631-1645.
5. Nakou ES, Liberopoulos EN, Milionis HJ, Elisaf MS. The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. Curr Vasc Pharmacol 2008; 6: 258-270.
6. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7: 678-689.
7. Schäfer A, Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol 2008; 6: 52-60.
8. McNicol A, Israels SJ. Beyond hemostasis: the role of platelets in inflammation, malignancy and infection. Cardiovasc Hematol Disord Drug Targets 2008; 8: 99-117.
9. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol 2009; 27: 165-197.
10. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-3347.
11. Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009; 48: 11-22.
12. Kaplan MJ. Management of cardiovascular disease risk in chronic inflammatory disorders. Nat Rev Rheumatol 2009; 5: 208-217.
13. Szekanecz Z, Koch AE. Vascular involvement in rheumatic diseases: 'vascular rheumatology'. Arthritis Res Ther 2008; 10: 224.
14. Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009; 161: 1-7.
15. Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009; 35: 313-324.
16. Mathieu S, Joly H, Baron G, et al. Trend towards increased arterial stiffness or intimamedia thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 2008; 47: 1203-1207.
17. Bilginer Y, Ozaltin F, Basaran C, et al. Evaluation of intima media thickness of the common and internal carotid arteries with inflammatory markers in familial Mediterranean fever as possible predictors for atherosclerosis. Rheumatol Int 2008; 28: 1211-1216.
18. Gasparyan AY, Ugurlucan M. The emerging issue of cardiovascular involvement in familial Mediterranean fever. Arch Med Sci 2008; 4: 465-467.
19. Chae JJ, Aksentijevich I, Kastner DL. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol 2009; 146: 467-478.
20. Gattorno M, La Regina M, Martini A, Manna R. An update on autoinflammatory diseases. New concepts for new and old diseases. Clin Exp Rheumatol 2009; 27: 354-365.
21. Fonnesu C, Cerquaglia C, Giovinale M, et al. Familial Mediterra-nean Fever: a review for clinical management. Joint Bone Spine 2009; 76: 227-233.
22. Centola M, Wood G, Frucht DM, et al. The gene for familial Medi-terranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 2000; 95: 3223-3231.
23. Ozen S, Bakkaloglu A, Yilmaz E, et al. Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? J Rheumatol 2003; 30: 2014-2018.
24. Kalyoncu M, Acar BC, Cakar N, et al. Are carriers for MEFV mutations healthy? Clin Exp Rheumatol 2006; 24 (5 Suppl 42): S120-122.
25. Candore G, Balistreri CR, Grimaldi MP, et al. Opposite role of pro-inflammatory alleles in acute myocardial infarction and longevity: results of studies performed in a Sicilian population. Ann NY Acad Sci 2006; 1067: 270-275.
26. Giaglis S, Mimidis K, Papadopoulos V, et al. Increased frequency of mutations in the gene responsible for familial Mediterranean fe-ver (MEFV) in a cohort of patients with ulcerative colitis: evidence for a potential disease-modifying effect? Dig Dis Sci 2006; 51: 687-692.
27. Atagunduz P, Ergun T, Direskeneli H. MEFV mutations are in-creased in Behçet's disease (BD) and are associated with vascular involvement. Clin Exp Rheumatol 2003; 21 (4 Suppl 30): S35-7.
28. Lachmann HJ, Sengül B, Yavuzşen TU, et al. Clinical and sub-clinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006; 45: 746-750.
29. Korkmaz C, Ozdogan H, Kasapçopur O, Yazici H. Acute phase response in familial Mediterranean fever. Ann Rheum Dis 2002; 61: 79-81.
30. Rozenbaum M, Naschitz JE, Yudashkin M, et al. Cardiovascular reactivity score for the assessment of dysautonomia in familial Mediterranean fever. Rheumatol Int 2004; 24: 147-152.
31. Caliskan M, Gullu H, Yilmaz S, et al. Impaired coronary microvas-cular function in familial Mediterranean fever. Atherosclerosis 2007; 195: e161-167.
32. Tavil Y, Ureten K, Oztürk MA, et al. The detailed assessment of left and right ventricular functions by tissue Doppler imaging in pa-tients with familial Mediterranean fever. Clin Rheumatol 2008; 27: 189-194.
33. Hamuryudan V, Ozdoǧan H, Yazici H. Other forms of vasculitis and pseudovasculitis. Baillieres Clin Rheumatol 1997; 11: 335-355.
34. Serrano R, Martínez MA, Andrés A, Morales JM, Samartin R. Familial mediterranean fever and acute myocardial infarction sec-ondary to coronary vasculitis. Histopathology 1998; 33: 163-167.
35. Cocco G. Vasculitis, left bundle branch block, and Raynaud's phenomenon as a manisfestation of familial Mediterranean fever. Arch Med Sci 2008; 4: 460-4.
36. Thurmon TF. Genetics, aging, and the heart. J La State Med Soc 1998; 150: 356-366.
37. Manna R, Cerquaglia C, Curigliano V, et al. Clinical features of familial Mediterranean fever: an Italian overview. Eur Rev Med Pharmacol Sci 2009; 13(Suppl 1): 51-53.
38. Lachmann HJ, Hawkins PN. Developments in the scientific and clinical understanding of autoinflammatory disorders. Arthritis Res Ther 2009; 11: 212.
39. Yildiz A, Akkaya V, Kiliçaslan I, et al. Cardiac and intestinal amy-loidosis in a renal transplant recipient with familial Mediterranean fever. J Nephrol 2001; 14: 125-127.
40. Keven K, Oztas E, Aksoy H, Duman N, Erbay B, Ertürk S. Poly-glandular endocrine failure in a patient with amyloidosis secondary to familial Mediterranean fever. Am J Kidney Dis 2001; 38: E39.
41. Gasparyan AY, Petrosyan AH. Cardiac involvement in familial Mediterranean fever. Cardiovas Ther Prevent (Moscow) 2007; 6 (6): 117-124.
42. Muller WA. Mechanisms of transendothelial migration of leuko-cytes. Circ Res 2009; 105: 223-230.
43. Wittchen ES. Endothelial signaling in paracellular and transcellular leukocyte transmigration. Front Biosci 2009; 14: 2522-2545.
44. Ungvári Z, Gupte SA, Recchia FA, Bátkai S, Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 2005; 3: 221-229.
45. Zalba G, Fortuño A, San José G, Moreno MU, Beloqui O, Díez J. Oxidative stress, endothelial dysfunction and cerebrovascular disease. Cerebrovasc Dis 2007; 24(Suppl 1): 24-29.
46. Direskeneli H, Ozdogan H, Korkmaz C, Akoglu T, Yazici H. Serum soluble intercellular adhesion molecule 1 and interleukin 8 levels in familial Mediterranean fever. J Rheumatol 1999; 26: 1983-1986.
47. Haznedaroglu S, Oztürk MA, Sancak B, et al. Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever. Clin Exp Rheumatol 2005; 23 (4 Suppl 38): 77-80.
48. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schön-beck U. Expression of interleukin (IL)-18 and functional IL-18 re-ceptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002; 195: 245-257.
49. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of in-terferon-gamma. Circ Res 2002; 90: E34-38.
50. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclero-sis: a comprehensive review of studies in mice. Cardiovasc Res 2008; 79: 360-376.
51. Ozbalkan Z, Ozturk MA, Onat AM, et al. Circulating thrombo-modulin levels in familial Mediterranean fever. Clin Exp Rheuma-tol 2006; 24 (5 Suppl 42): 95-98.
52. Balat A, Işlek I, Cekmen M, et al. Adrenomedullin and total nitrite levels in children with familial Mediterranean fever. J Paediatr Child Health 2006; 42: 240-243.
53. Terekeci HM, Oktenli C, Ozgurtas T, et al. Increased asymmetric dimethylarginine levels in young men with familial Mediterranean fever (FMF): is it early evidence of interaction between inflamma-tion and endothelial dysfunction in FMF? J Rheumatol 2008; 35: 2024-2029.
54. Gunesacar R, Erken E, Ozer HT, Bozkurt B, Dinkci S, Deveci D. Analysis of vascular endothelial growth factor gene 936 C/T polymorphism in patients with familial Mediterranean fever. Int J Immunogenet 2008; 35: 33-36.
55. Başar O, Oztürk MA, Köklü S, et al. Plasma levels of soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) in familial Mediterranean fever. Joint Bone Spine 2007; 74: 52-55.
56. Aksu G, Ozturk C, Kavakli K, Genel F, Kutukculer N. Hyper-coagulability: interaction between inflammation and coagulation in familial Mediterranean fever. Clin Rheumatol 2007; 26: 366-370.
57. Demirel A, Celkan T, Kasapcopur O, et al. Is Familial Mediterra-nean Fever a thrombotic disease or not? Eur J Pediatr 2008; 167: 279-285.
58. Aoun EG, Musallam KM, Uthman I, Beydoun A, El-Hajj T, Taher AT. Childhood stroke in a child with familial Mediterranean fever carrying several prothrombotic risk factors. Lupus 2009; 18: 845-847.
59. Sari S, Egritas O, Bukulmez A, Dalgic B, Soylemezoglu O. Is familial mediterranean fever a possible cofactor for budd-chiari syndrome? J Pediatr Gastroenterol Nutr 2009; 49(4): 481-484.
60. Ozel Demiralp DF, Ekim M, Akar N. The effect of plasminogen activator inhibitor-1-675 4G/5G polymorphism on Familial Mediterranean Fever (FMF) Disease. Clin Appl Thromb Hemost 2009; 15(4): 443-447.
61. Rabinovich E, Shinar Y, Leiba M, Ehrenfeld M, Langevitz P, Liv-neh A. Common FMF alleles may predispose to development of Behcet's disease with increased risk for venous thrombosis. Scand J Rheumatol 2007; 36: 48-52.
62. Coban E, Adanir H. Platelet activation in patients with Familial Mediterranean Fever. Platelets 2008; 19: 405-408.
63. Makay B, Türkyilmaz Z, Unsal E. Mean platelet volume in chil-dren with familial Mediterranean fever. Clin Rheumatol 2009; 28: 975-978.
64. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003; 23: 2131-2137.
65. Smid J, Braun-Dullaeus R, Gawaz M, Langer HF. Platelet interac-tions as therapeutic targets for prevention of atherothrombosis. Future Cardiol 2009; 5: 285-296.
66. Bots ML. Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies. Curr Med Res Opin 2006; 22: 2181-2190.
67. Gasparyan AY. The use of carotid artery ultrasonography in differ-ent clinical conditions. Open Cardiovasc Med J 2009; 3: 78-80.
68. Sari I, Karaoglu O, Can G, et al. Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever. Clin Rheumatol 2007; 26: 1467-1473.
69. Akdogan A, Calguneri M, Yavuz B, et al. Are familial Mediterra-nean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF. J Am Coll Cardiol 2006; 48: 2351-2353.
70. Peru H, Altun B, Doǧan M, Kara F, Elmaci AM, Oran B. The evaluation of carotid intima-media thickness in children with famil-ial Mediterranean fever. Clin Rheumatol 2008; 27: 689-694.
71. Ugurlu S, Seyahi E, Cetinkaya F, Ozbakir F, Balci H, Ozdogan H. Intima-media thickening in patients with familial Mediterranean fever. Rheumatology (Oxford) 2009; 48: 911-915.
72. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 1998; 28: 48-59.
73. Niel E, Scherrmann JM. Colchicine today. Joint Bone Spine 2006; 73: 672-678.
74. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med 1972; 287: 1302.
75. Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med 1974; 291: 934-7.
76. Goldfinger SE. Familial Mediterranean fever--a progress report. West J Med 1977; 127: 40-41.
77. Cerquaglia C, Diaco M, Nucera G, La Regina M, Montalto M, Manna R. Pharmacological and clinical basis of treatment of Famil-ial Mediterranean Fever (FMF) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy 2005; 4: 117-124.
78. Ben-Chetrit E, Levy M. Does the lack of the P-glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other inflammatory diseases? Med Hypotheses 1998; 51: 377-380.
79. Abedat S, Urieli-Shoval S, Shapira E, Calko S, Ben-Chetrit E, Matzner Y. Effect of colchicine and cytokines on MEFV expres-sion and C5a inhibitor activity in human primary fibroblast cul-tures. Isr Med Assoc J 2002; 4: 7-12.
80. Ben-Chetrit E, Bergmann S, Sood R. Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis. Rheumatology (Oxford) 2006; 45: 274-282.
81. Entzian P, Schlaak M, Seitzer U, Bufe A, Acil Y, Zabel P. Antiin-flammatory and antifibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis. Lung 1997; 175: 41-51.
82. De Socio G, Cerquaglia C, Curigliano V, et al. Association between familial mediterranean fever and retroperitoneal fibrosis: retroperitoneal fibrosis regression after colchicine therapy. Int J Immunopathol Pharmacol 2009; 22: 521-524.
83. Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med 2005; 165: 1987-1991.
84. Gasparyan AY. Effect of colchicine on ventricular diastolic reserve and pulmonary blood flow state in familial Mediterranean fever. J Arrhythmology (Saint-Petersburg) 2001; (24): 27-30.
85. Langevitz P, Livneh A, Neumann L, et al. Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J 2001; 3: 9-12.
86. Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol 2007; 99: 805-807.
87. Atta HM, El-Rehany MA, Abdel Raheim SR, Fouad R, Galal AM. Colchicine inhibits intimal hyperplasia and leukocyte VEGF expression in dogs. J Surg Res 2008; 146: 184-189.